Ohr Pharmceutial Cm (OHRP) 2.73 $OHRP
OHR reports 2Q loss
Automated Insights - Tue May 10, 4:18PM CDT
NEW YORK (AP) _ Ohr Pharmaceutical Inc. (OHRP) on Tuesday reported a loss of $5.3 million in its fiscal second quarter.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Reports Second Quarter 2016 Financial and Business Results
GlobeNewswire - Tue May 10, 4:06PM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its second quarter ended March 31, 2016.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee
GlobeNewswire - Mon May 02, 7:00AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that David M. Brown, MD, Clinical Professor of Ophthalmology at Baylor College of Medicine, vice-chair for research at the Blanton Eye Institute, Houston Methodist Hospital, and partner at Retina Consultants of Houston, has been appointed to serve as the chair of the Steering Committee for the Phase 3 clinical program of squalamine lactate ophthalmic solution, 0.2% ("Squalamine," also known as OHR-102) in wet-AMD. The steering committee will support the Phase 3 clinical development program, enhance the interactions with clinical investigators, and help to ensure the timely achievement of study milestones.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Announces Presentations at the 2016 Association for Research in Vision and Ophthalmology (ARVO) Conference in Seattle, WA
GlobeNewswire - Wed Apr 27, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the details of two poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Conference, taking place May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.
OHRP: 2.73 (-0.02)
Biotech Companies That Are Progressing Rapidly
ACCESSWIRE - Mon Apr 04, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 4, 2016 / When investing in speculative biotechnology stocks one of the most important factors is cash flow. Does the company have enough financing to get through trials? Because if not, it doesn't matter how fantastic the potential of its treatment or drug may be, if it doesn't have the financial wherewithal to reach that point.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 4.28 (unch), OHRP: 2.73 (-0.02)
Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program
GlobeNewswire - Tue Mar 29, 6:00AM CDT
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that it has reached an agreement on the Special Protocol Assessment (SPA) with the United States Food and Drug Administration (US FDA) on the design of the Phase III trial for its lead drug candidate, squalamine lactate ophthalmic solution, 0.2% ("Squalamine," also known as OHR-102). Based on the agreed upon SPA, Ohr has initiated the first of two planned Phase III global clinical studies evaluating the efficacy and safety of Squalamine, given in combination with Lucentis, for the treatment of neovascular age-related macular degeneration (wet AMD).
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Reports First Quarter 2016 Financial and Business Results
GlobeNewswire - Tue Feb 09, 3:01PM CST
Conference Call Today at 5:00pm Eastern Time
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical to Present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York
GlobeNewswire - Tue Feb 09, 8:48AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York, NY.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical to Announce First Quarter 2016 Financial Results on February 9
GlobeNewswire - Wed Feb 03, 7:00AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the first quarter ended December 31, 2015 after the market close on Tuesday, February 9, 2016. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.
OHRP: 2.73 (-0.02)
Jazz's Phase III Data on Defibrotide Published in ASH Journal
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 3:40PM CST
Jazz Pharmaceuticals (JAZZ) announced that results from a pivotal phase III study on defibrotide were published online in BLOOD.
JAZZ: 150.97 (-1.85), OHRP: 2.73 (-0.02), BXLT: 46.02 (-0.18), ANIK: 49.92 (+0.70)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.05 (-0.48), PFE: 36.89 (+0.22), OPHT: 64.24 (-0.79), PFNX: 8.07 (+0.04), OCUL: 4.37 (-0.13), AGN: 252.95 (-2.61), GTXI: 0.55 (-0.01), OHRP: 2.73 (-0.02), AAVL: 4.14 (-0.18), TCON: 5.10 (+0.07), REGN: 425.12 (+14.08), NVS: 83.26 (+1.18)
Retinal Vein Occlusion Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/prcfm8/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinal Vein Occlusion Overview - Therapeutics Development - Pipeline Products for Retinal Vein Occlusion - Overview - Pipeline Products for Retinal Vein Occlusion - Comparative Analysis - Retinal Vein Occlusion - Therapeutics under Development by Companies - Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes - Retinal Vein Occlusion - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinal Vein Occlusion - Products under Development by Companies - Retinal Vein Occlusion - Products under Investigation by Universities/Institutes - Retinal Vein Occlusion - Companies Involved in Therapeutics Development - Aerpio Therapeutics, Inc. - Allergan Plc - Avalanche Biotechnologies, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/pr...tinal_vein
AGN: 252.95 (-2.61), EYEG: 2.02 (-0.11), OHRP: 2.73 (-0.02), AAVL: 4.14 (-0.18)
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 8:30AM CST
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
UTHR: 121.01 (+2.02), AERI: 17.35 (-0.19), INFI: 1.68 (+0.06), OHRP: 2.73 (-0.02), PCRX: 36.25 (-1.22)
6 Drug Stocks That Look to Beat the Market in 2016
Zacks Equity Research - Zacks Investment Research - Mon Jan 18, 3:50PM CST
Don't miss these drug stocks that look to beat the market in 2016.
UTHR: 121.01 (+2.02), PFE: 36.89 (+0.22), AERI: 17.35 (-0.19), ANAC: 99.06 (-0.14), OHRP: 2.73 (-0.02), INFI: 1.68 (+0.06), PCRX: 36.25 (-1.22)
OHR reports 2Q loss
Automated Insights - Tue May 10, 4:18PM CDT
NEW YORK (AP) _ Ohr Pharmaceutical Inc. (OHRP) on Tuesday reported a loss of $5.3 million in its fiscal second quarter.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Reports Second Quarter 2016 Financial and Business Results
GlobeNewswire - Tue May 10, 4:06PM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its second quarter ended March 31, 2016.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee
GlobeNewswire - Mon May 02, 7:00AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that David M. Brown, MD, Clinical Professor of Ophthalmology at Baylor College of Medicine, vice-chair for research at the Blanton Eye Institute, Houston Methodist Hospital, and partner at Retina Consultants of Houston, has been appointed to serve as the chair of the Steering Committee for the Phase 3 clinical program of squalamine lactate ophthalmic solution, 0.2% ("Squalamine," also known as OHR-102) in wet-AMD. The steering committee will support the Phase 3 clinical development program, enhance the interactions with clinical investigators, and help to ensure the timely achievement of study milestones.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Announces Presentations at the 2016 Association for Research in Vision and Ophthalmology (ARVO) Conference in Seattle, WA
GlobeNewswire - Wed Apr 27, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the details of two poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Conference, taking place May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.
OHRP: 2.73 (-0.02)
Biotech Companies That Are Progressing Rapidly
ACCESSWIRE - Mon Apr 04, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 4, 2016 / When investing in speculative biotechnology stocks one of the most important factors is cash flow. Does the company have enough financing to get through trials? Because if not, it doesn't matter how fantastic the potential of its treatment or drug may be, if it doesn't have the financial wherewithal to reach that point.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 4.28 (unch), OHRP: 2.73 (-0.02)
Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program
GlobeNewswire - Tue Mar 29, 6:00AM CDT
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that it has reached an agreement on the Special Protocol Assessment (SPA) with the United States Food and Drug Administration (US FDA) on the design of the Phase III trial for its lead drug candidate, squalamine lactate ophthalmic solution, 0.2% ("Squalamine," also known as OHR-102). Based on the agreed upon SPA, Ohr has initiated the first of two planned Phase III global clinical studies evaluating the efficacy and safety of Squalamine, given in combination with Lucentis, for the treatment of neovascular age-related macular degeneration (wet AMD).
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical Reports First Quarter 2016 Financial and Business Results
GlobeNewswire - Tue Feb 09, 3:01PM CST
Conference Call Today at 5:00pm Eastern Time
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical to Present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York
GlobeNewswire - Tue Feb 09, 8:48AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York, NY.
OHRP: 2.73 (-0.02)
Ohr Pharmaceutical to Announce First Quarter 2016 Financial Results on February 9
GlobeNewswire - Wed Feb 03, 7:00AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the first quarter ended December 31, 2015 after the market close on Tuesday, February 9, 2016. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.
OHRP: 2.73 (-0.02)
Jazz's Phase III Data on Defibrotide Published in ASH Journal
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 3:40PM CST
Jazz Pharmaceuticals (JAZZ) announced that results from a pivotal phase III study on defibrotide were published online in BLOOD.
JAZZ: 150.97 (-1.85), OHRP: 2.73 (-0.02), BXLT: 46.02 (-0.18), ANIK: 49.92 (+0.70)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.05 (-0.48), PFE: 36.89 (+0.22), OPHT: 64.24 (-0.79), PFNX: 8.07 (+0.04), OCUL: 4.37 (-0.13), AGN: 252.95 (-2.61), GTXI: 0.55 (-0.01), OHRP: 2.73 (-0.02), AAVL: 4.14 (-0.18), TCON: 5.10 (+0.07), REGN: 425.12 (+14.08), NVS: 83.26 (+1.18)
Retinal Vein Occlusion Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/prcfm8/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinal Vein Occlusion Overview - Therapeutics Development - Pipeline Products for Retinal Vein Occlusion - Overview - Pipeline Products for Retinal Vein Occlusion - Comparative Analysis - Retinal Vein Occlusion - Therapeutics under Development by Companies - Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes - Retinal Vein Occlusion - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinal Vein Occlusion - Products under Development by Companies - Retinal Vein Occlusion - Products under Investigation by Universities/Institutes - Retinal Vein Occlusion - Companies Involved in Therapeutics Development - Aerpio Therapeutics, Inc. - Allergan Plc - Avalanche Biotechnologies, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/pr...tinal_vein
AGN: 252.95 (-2.61), EYEG: 2.02 (-0.11), OHRP: 2.73 (-0.02), AAVL: 4.14 (-0.18)
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 8:30AM CST
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
UTHR: 121.01 (+2.02), AERI: 17.35 (-0.19), INFI: 1.68 (+0.06), OHRP: 2.73 (-0.02), PCRX: 36.25 (-1.22)
6 Drug Stocks That Look to Beat the Market in 2016
Zacks Equity Research - Zacks Investment Research - Mon Jan 18, 3:50PM CST
Don't miss these drug stocks that look to beat the market in 2016.
UTHR: 121.01 (+2.02), PFE: 36.89 (+0.22), AERI: 17.35 (-0.19), ANAC: 99.06 (-0.14), OHRP: 2.73 (-0.02), INFI: 1.68 (+0.06), PCRX: 36.25 (-1.22)
